Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Executive Summary
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
You may also be interested in...
Qiagen CFO Sees COVID Diagnostics Volatility Continuing In 2022
Qiagen’s doubled-down focus on PCR technologies in late 2019 proved to be fortuitous, but future growth will come from many other drivers, says CFO Roland Sackers.
Qiagen Ready To Rival Abbott With Rapid, Portable Antigen COVID-19 Test
The diagnostics company said the test is scheduled for US launch in Q4 2020.
Qiagen Terminates Thermo Fisher Deal After Shareholders Reject Last Offer
Qiagen's shareholders said Thermo Fisher's final offer price for the diagnostics company was too low.